NEW YORK (GenomeWeb) – Genomic Expression and the Kew Group will collaborate to launch Kew's next-generation sequencing-based cancer panel in Scandinavia, the companies said this week.
Kew's CancerPlex assay uses Thermo Fisher's Ion Torrent PGM to analyze over 400 known cancer genes involved in initiation and progression.
The companies will use Kew's panel and Genomic Expression's sample evaluation and informatics technologies.
"Our united ability to bring large-scale oncology genomic profiling to Scandinavian cancer patients represents a dramatic improvement in current diagnostic options," Kew Group CEO Scott Schell said in a statement.
Genomic Expression CEO Gitte Pedersen added that "the comprehensive analysis of known actionable genes in the CancerPlex assay is immediately valuable for patients in selecting more effective treatments and avoiding treatments that don't prolong life."